Beta-bloqueante

Applications N-Fmoc-L-cysteine is the N-Fmoc-protected form of L-Cysteine (C995000), a non-essential α-amino acid that is biosynthesized in humans. L-Cysteine is also a bicarbonate-sensitive endogenous excitotoxin in rats and possibly humans. References Li, Q. et al.: Mat. Lett., 64, 614 (2010); Olney, J., et al.: Science, 4, 596 (1990)

Ether-alcohols and their halogenated, sulfonated, nitrated or nitrosated derivatives not elsewhere specified or included

Aromatic or modified aromatic drugs with nitrogen hetero-atom(s) only, not elsewhere specified or included

Stability Light Sensitive, Temperature Sensitive Applications An Atorvastatin (A791750) derivative which have improved stability.

Applications Labelled Clopridogrel, an antithrombotic.A representative lot was: 4.2% d3, 0.07% d2, 0.0005% d1 and no d0 were detected. References Mills, D.C.B., et al.: Arterioscler. Thromb., 12, 430 (1992), Feuerstein, G., et al.: Exp. Opin. Invest. Drugs, 4, 425 (1995)

Applications A labelled active form of folic acid used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine among other functions. It is a coenzymated form of folic acid. It has been proposed for treatment of cardiovascular disease. References Willems, F. et al.: Br. J. Pharmacol., 145, 823 (2004); Prinz-Langhebohi, R.: et al., Br. J. Pharmacol., 158, 2014 (2009); Wright, A. et al.: Brit, J. Nutrit., 103, 724 (2010)

Applications A metabolite of Carvedilol (C184625). References McGurk, K., et al.: Biochem. Pharmacol., 55, 1005 (1998), Tukey, R., et al.: Annu. Rev. Pharmacol. Toxicol., 40, 581 (2000), Bowalgaha, K., et al.: Br. J. Clin. Pharmacol., 52, 605 (2001), Richardson, T., et al.: Drug Metab. Dispos., 34, 351 (2006),

Applications Pimobendan is a cardiotonic agent. The study of the cardiotonic mechanism of Pimobendan using ventricular muscles from rabbits and guinea pigs suggests that Pimobendan acts by inhibiting phosphodiesterase III and potassium channel. The potent venodilating action of Pimobendan makes it a suitable treatment option for patients with congestive heart failure (CHF) as it also improves systemic vasoconstriction. References Yokota, S. et al.: Yakuri Chiryo, 20, 1143 (1992); Yamamoto, M. et al.: Kank. Igaku Ken. Nenpo, 47, 155 (1996); Matsumoto, A. et al.: Cardiovas. Drugs Ther., 12, 595 (1998);

Applications α2-Adrenoceptor agonist related structurally to Clonidine. Used in treatment of opioid withdrawal symptoms; antihypertensive. Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package References Velly, J., et al.: J. Pharmacol., 8, 351 (1977), Jarrot, B., et al.: Biochem. Pharmacol., 28, 141 (1979), Birch, P., at al.: Brit. J. Pharmacol., 68, 107 (1980),